U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399795) titled 'Citalopram and the Risk of Serious Adverse Events' on Jan. 28.
Brief Summary: This population-based cohort study aims to evaluate the safety of initiating a new outpatient prescription of citalopram at 20 mg/day (higher dose) compared to 10 mg/day (lower dose) in adults aged 65 years and older with reduced kidney function. The primary research question is whether initiating a higher dose of citalopram (20 mg/day) versus a lower dose (10 mg/day) in older adults with low kidney function (defined as an estimated glomerular filtration rate [eGFR] less than 45 mL/min per 1.73 m2, without dialysis or a history of kidney transplantation) i...